In This Article:
Medical device company DexCom (NASDAQ:DXCM) will be reporting results tomorrow after market hours. Here’s what to look for.
DexCom beat analysts’ revenue expectations by 0.9% last quarter, reporting revenues of $1.11 billion, up 7.6% year on year. It was a slower quarter for the company, with a significant miss of analysts’ EPS estimates.
Is DexCom a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting DexCom’s revenue to grow 10.5% year on year to $1.02 billion, slowing from the 24.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.33 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. DexCom has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 1.5% on average.
Looking at DexCom’s peers in the healthcare equipment and supplies segment, some have already reported their Q1 results, giving us a hint as to what we can expect. ResMed delivered year-on-year revenue growth of 7.9%, meeting analysts’ expectations, and Penumbra reported revenues up 16.3%, topping estimates by 2.7%. ResMed traded up 10.1% following the results while Penumbra was also up 7.2%.
Read our full analysis of ResMed’s results here and Penumbra’s results here.
Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.6% on average over the last month. DexCom is up 5.9% during the same time and is heading into earnings with an average analyst price target of $99.12 (compared to the current share price of $71.30).
Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.